文献速递乳腺癌

密集剂量表柔比星、紫杉醇、环磷酰胺对比每周紫杉醇、脂质体多柔比星(三阴性乳腺癌加卡铂)用于高危早期乳腺癌新辅助治疗(GeparOcto-GBG 84):一项随机III期试验

Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
PubMed 文献 · Eur J Cancer · 2018-12-05

GeparOcto研究比较两种化疗方案在高危早期乳腺癌中的疗效与安全性:序贯密集剂量表柔比星、紫杉醇、环磷酰胺(iddEPC)与每周紫杉醇联合非聚乙二醇脂质体多柔比星(PM),三阴性乳腺癌加卡铂(PM(Cb))。945例开始治疗,iddEPC组pCR率48.3%,PM(Cb)组48.0%,无显著差异;PM(Cb)组因不良事件停药比例更高(34.1% vs 16.4%,P<0.001)。

要点

  • iddEPC与PM(Cb)的新辅助pCR率分别为48.3%和48.0%,无显著差异(OR 0.99,95%CI 0.77-1.28,P=0.979)。
  • 三阴性、HER2阳性及luminal B样亚型中两组pCR率均无显著差异。
  • PM(Cb)组停药比例34.1%,iddEPC组16.4%(P<0.001),停药主要因不良事件;PM(Cb)组有2例死亡。

核心结论

  • 在高危早期乳腺癌中,iddEPC与每周PM(Cb)新辅助治疗的pCR率无差异。
  • iddEPC是日常实践中可行的一种有效密集剂量方案。

研究设计与样本

  • 随机III期试验GeparOcto-GBG 84,纳入cT1c-cT4a-d且中心评估为HER2阳性或三阴性乳腺癌患者,不限淋巴结状态,luminal B样肿瘤仅限pN+。
  • 按乳腺癌亚型、Ki67、淋巴细胞为主型乳腺癌分层随机。
  • iddEPC方案:表柔比星150 mg/m2,序贯紫杉醇225 mg/m2,序贯环磷酰胺2000 mg/m2,每2周1次,各3周期,共18周。
  • PM(Cb)方案:每周紫杉醇80 mg/m2联合非聚乙二醇脂质体多柔比星20 mg/m2,三阴性乳腺癌加卡铂AUC 1.5。
  • HER2阳性患者在所有含紫杉醇和环磷酰胺周期加用曲妥珠单抗(负荷剂量8 mg/kg,后续6 mg/kg,每3周)和帕妥珠单抗(负荷剂量840 mg,后续420 mg,每3周)。

主要发现

  • iddEPC组pCR率为48.3%,PM(Cb)组为48.0%(PM(Cb)对比iddEPC的OR 0.99;95%CI 0.77-1.28,P=0.979)。
  • 三阴性、HER2阳性、luminal B样亚型中两组pCR率均无显著差异。
  • iddEPC组16.4%停药,PM(Cb)组34.1%停药(P<0.001),停药主要因不良事件。
  • PM(Cb)组有2例患者死亡。

关键数值与推荐

  • 主要终点为病理完全缓解(pCR,ypT0/is ypN0)。
  • 次要终点包括其他pCR定义、分层亚组中的pCR、耐受性和依从性。

临床怎么用

  • 在高危早期乳腺癌新辅助治疗中,iddEPC与每周PM(Cb)的pCR率无差异,iddEPC是日常实践中可行的一种有效密集剂量方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: GeparOcto compared efficacy and safety of two chemotherapy regimens in high-risk early breast cancer (BC): sequential treatment with intense dose-dense epirubicin, paclitaxel, and cyclophosphamide (iddEPC) and weekly treatment with paclitaxel plus non-pegylated liposomal doxorubicin (M, Myocet®) with additional carboplatin (PM(Cb)) in triple-negative BC (TNBC). PATIENTS AND METHODS: Patients with cT1c-cT4a-d and centrally assessed human epidermal growth factor receptor (HER)2-positive BC or TNBC were eligible, irrespective of nodal status, luminal B-like tumours only if pN+. Patients were randomised (stratified by BC subtype, Ki67, lymphocyte-predominant BC) to receive 18 weeks of E (150 mg/m2) followed by P (225 mg/m2) followed by C (2000 mg/m2), each q2w for 3 cycles or weekly P (80 mg/m2) plus M (20 mg/m2) plus, in TNBC, Cb (area under curve (AUC) 1.5). HER2-positive BC patients additionally received trastuzumab (6 [loading dose 8]mg/kg q3w) and pertuzumab (420 [840]mg q3w) with all P and C cycles. Primary end-point was pathological complete response (pCR, ypT0/is ypN0), secondary end-points included other pCR definitions, pCR in stratified subpopulations, tolerability and compliance. This trial is registered with ClinicalTrials.gov number NCT02125344. RESULTS: 945/961 randomised patients started treatment. The median age was 48 years; 7.6% had cT3-4, 46% cN+, 66% G3, 40% HER2-positive, 43% TNBC. pCR rate with iddEPC was 48.3%, with PM(Cb) 48.0%, respectively (PM(Cb) versus iddEPC odds ratio 0.99; 95% confidence interval 0.77-1.28, P = 0.979) with no significant differences observed in TNBC, HER2-positive, luminal B-like subtypes. 16.4% with iddEPC and 34.1% with PM(Cb) discontinued treatment (P < 0.001), mainly due to adverse events; two patients on PM(Cb) died. CONCLUSIONS: In high-risk early BC there is no difference in pCR rates following neoadjuvant treatment with iddEPC or weekly PM(Cb), respectively. iddEPC is one of the effective dose-dense regimens feasible in daily practice.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schneeweiss A, Möbus V, Tesch H, et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Eur J Cancer. 2018. PMID: 30528802. doi:10.1016/j.ejca.2018.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。